GEADV Editorial Team Highlights Journal Advances, Personalized Dermatology, and Emerging Research

Conclusions

• The presentation concludes that JEADV aims to translate high-quality dermatology research into better patient care through evidence-based articles, guidelines, podcasts, and patient-facing content.
• Methotrexate remains an important and effective option for carefully selected patients with erythrodermic mycosis fungoides, especially when personalized to the right disease subtype.
• Biologics are supported by robust evidence for pediatric psoriasis, with secukinumab showing durable long-term efficacy and acceptable safety in children.
• In hidradenitis suppurativa, bimekizumab appears to provide the fastest and strongest short-term biologic response among the compared agents.
• Updated atopic eczema guidelines support a stepped-care, personalized approach and incorporate newer agents such as dupilumab, tralokinumab, baricitinib, and abrocitinib.
• Management of EGFR-inhibitor acneiform rash still needs stronger evidence, but preemptive skin care and antibiotics are increasingly being used in practice.
• Advanced imaging tools, including ultrasound, OCT, confocal microscopy, and even simple smartphone-based techniques, can improve diagnosis of nail disorders and sometimes outperform waiting for cultures.
• Environmental responsibility is becoming part of dermatologic practice, with a push to reduce plastic use and rethink samples and packaging.
• Precision dermatology is moving toward transcriptomics, AI-based prediction, proteomics, and model-informed dosing to match treatments to individual patients rather than using one-size-fits-all therapy.
• In bullous pemphigoid, proteomic data suggest CCL13 and IL-13 may be more relevant biomarkers and therapeutic targets than IL-4.
• Biologic dosing in atopic dermatitis can often be safely extended in selected patients, but treatment should be returned to standard intervals if disease control worsens.
• The future of dermatology is portrayed as technology-enabled and predictive, with the dermatologist acting as an orchestrator of AI, digital monitoring, and individualized treatment.
• Resistance to terbinafine in Trichophyton indotineae and azole resistance in Candida glabrata are emerging problems that require vigilance and action.
• Building and training junior editors is an effective solution to reviewer shortages and also creates a successful pipeline for future scholarly contributors.
• Including patient voice articles and plain-language summaries strengthens the journal’s educational mission and helps reveal unmet patient needs, especially in rare diseases like Darier disease.